Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
86
Views
33
CrossRef citations to date
0
Altmetric
Review

The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers

Joshua K Sabari1 Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center
,
Fernando C Santini1 Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center;2 Developmetal Therapeutics, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center
,
Alison M Schram2 Developmetal Therapeutics, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center
,
Isabella Bergagnini1 Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center
,
Ruqin Chen1 Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center
,
Chebli Mrad1 Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center
,
W Victoria Lai1 Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center
,
Kathryn C Arbour1 Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center
&
Alexander Drilon2 Developmetal Therapeutics, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center;3 Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USACorrespondence[email protected]
 show all
Pages 1983-1992 | Published online: 06 Apr 2017

Citations (33)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Akito Fukuda & Tatsuya Yoshida. (2023) Treatment of advanced ALK-rearranged NSCLC following second-generation ALK–TKI failure. Expert Review of Anticancer Therapy 23:11, pages 1157-1167.
Read now
Bin Yao, Xue Han, Linrong Pang, Caihong Xu, Sisi Liu, Xiaochun Cheng & Jun Chen. (2021) Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report. OncoTargets and Therapy 14, pages 4329-4333.
Read now
Robert Ali, Junaid Arshad, Sofia Palacio & Raja Mudad. (2019) Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy. Drug Design, Development and Therapy 13, pages 569-580.
Read now
G. Hamilton & M.J. Hochmair. (2019) An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer. Expert Opinion on Pharmacotherapy 20:13, pages 1551-1561.
Read now
Takaki Akamine, Gouji Toyokawa, Tetsuzo Tagawa & Takashi Seto. (2018) Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date. OncoTargets and Therapy 11, pages 5093-5101.
Read now
Rohit K Jain & Hongbin Chen. (2017) Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib. Lung Cancer: Targets and Therapy 8, pages 169-177.
Read now

Articles from other publishers (27)

Rachel S. Kim, Michael K. Nguyen, Kevin R. Card & Carol L. Shields. (2023) Utility of systemic brigatinib therapy in tumour recurrence of choroid metastasis from non–small cell lung carcinoma. Canadian Journal of Ophthalmology.
Crossref
Koichi Ando, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori & Hironori Sagara. (2023) Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis. International Journal of Molecular Sciences 24:3, pages 2242.
Crossref
Zixi Wang, Yurou Xing, Bingjie Li, Xiaoyu Li, Bin Liu & Yongsheng Wang. (2022) Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. Molecular Biomedicine 3:1.
Crossref
David S. EttingerDouglas E. WoodDara L. AisnerWallace AkerleyJessica R. BaumanAnkit BharatDebora S. BrunoJoe Y. ChangLucian R. ChirieacThomas A. D’AmicoMalcolm DeCampThomas J. DillingJonathan DowellScott GettingerTravis E. GrotzMatthew A. GubensAparna HegdeRudy P. LacknerMichael LanutiJules LinBilly W. LooChristine M. LovlyFabien MaldonadoErminia MassarelliDaniel MorgenszternThomas NgGregory A. OttersonJose M. PachecoSandip P. PatelGregory J. RielyJonathan RiessSteven E. SchildTheresa A. ShapiroAditi P. SinghJames StevensonAlda TamTawee TanvetyanonJane YanagawaStephen C. YangEdwin Yau, Kristina Gregory & Miranda Hughes. (2022) Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 20:5, pages 497-530.
Crossref
Mustafa Kamal Pasha, Ishrat Jabeen & Sandhya Samarasinghe. (2022) 3D QSAR and pharmacophore studies on inhibitors of insuline like growth factor 1 receptor (IGF-1R) and insulin receptor (IR) as potential anti-cancer agents. Current Research in Chemical Biology 2, pages 100019.
Crossref
Bin Wang, Hanfei Guo, Haiyang Xu, Hongquan Yu, Yong Chen & Gang Zhao. (2021) Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer. Cells 10:10, pages 2620.
Crossref
Yue Pan, Chao Deng, Zhenhua Qiu, Chenghui Cao & Fang Wu. (2021) The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer. Frontiers in Oncology 11.
Crossref
Saad M. Alshahrani, Munerah M. Alfadhel, Khalil Y.R. Abujheisha, Bjad K. Almutairy, Ahmed S. Alalaiwe, Abdullah S. Alshetaili, Mohammed F. Aldawsari, Md. Khalid Anwer & Faiyaz Shakeel. (2021) Solubility determination, computational modeling, Hansen solubility parameters and apparent thermodynamic analysis of brigatinib in (ethanol + water) mixtures. Zeitschrift für Physikalische Chemie 235:8, pages 961-975.
Crossref
Koichi Ando, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori & Hironori Sagara. (2021) Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis. Cancers 13:15, pages 3704.
Crossref
Richard A. Ward, Stephen Fawell, Nicolas Floc’hVikki FlemingtonDarren McKerrecherPaul D. Smith. (2020) Challenges and Opportunities in Cancer Drug Resistance. Chemical Reviews 121:6, pages 3297-3351.
Crossref
Enric Carcereny, Alonso Fernández-Nistal, Araceli López, Carmen Montoto, Andrea Naves, Cristina Segú-Vergés, Mireia Coma, Guillem Jorba, Baldomero Oliva & Jose Manuel Mas. (2021) Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach . Oncotarget 12:4, pages 316-332.
Crossref
David Heredia, Feliciano Barrón, Andrés F. Cardona, Saul Campos, Jerónimo Rodriguez-Cid, Luis Martinez-Barrera, Jorge Alatorre, Miguel Ángel Salinas, Luis Lara-Mejia, Diana Flores-Estrada & Oscar Arrieta. (2021) Brigatinib in ALK -positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP) . Future Oncology 17:2, pages 169-181.
Crossref
Ning Sun, Chaowei Ren, Ying Kong, Hui Zhong, Jinju Chen, Yan Li, Jianshui Zhang, Yuedong Zhou, Xing Qiu, Haifan Lin, Xiaoling Song, Xiaobao Yang & Biao Jiang. (2020) Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. European Journal of Medicinal Chemistry 193, pages 112190.
Crossref
Koichi Ando, Kaho Akimoto, Hiroki Sato, Ryo Manabe, Yasunari Kishino, Tetsuya Homma, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori & Hironori Sagara. (2020) Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis. Cancers 12:4, pages 942.
Crossref
Chao Zhang, Natasha B. Leighl, Yi-Long Wu & Wen-Zhao Zhong. (2019) Emerging therapies for non-small cell lung cancer. Journal of Hematology & Oncology 12:1.
Crossref
Stewart Umbela, Shahinaz Ghacha, Revika Matuknauth, Stacey Gause, Shrijana Joshee & Rahul R. Deshmukh. (2019) Brigatinib: New-generation ALK inhibitor for nonsmall cell lung cancer. Current Problems in Cancer 43:6, pages 100477.
Crossref
Simon S. Terzyan, Tao Shen, Xuan Liu, Qingling Huang, Peng Teng, Mi Zhou, Frank Hilberg, Jianfeng Cai, Blaine H.M. Mooers & Jie Wu. (2019) Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib. Journal of Biological Chemistry 294:27, pages 10428-10437.
Crossref
Hiu Ting Chan, Yoon Ming Chin & Siew-Kee Low. (2019) The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics. Oncology and Therapy 7:1, pages 1-32.
Crossref
Meijuan Ding, Lili Deng, Ruoying Yu, Dan Lu, Yun Bai, Xue Wu, Yang W. Shao & Yu Yang. (2019) Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI–Treated Non–Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy. Clinical Lung Cancer 20:3, pages e229-e232.
Crossref
Richard A. Blidner, Brian C. Haynes, Stephen Hyter, Sarah Schmitt, Ziyan Y. Pessetto, Andrew K. Godwin, Dan Su, Patrick Hurban, Léon C. van Kempen, Maria L. Aguirre, Shobha Gokul, Robyn D. Cardwell & Gary J. Latham. (2019) Design, Optimization, and Multisite Evaluation of a Targeted Next-Generation Sequencing Assay System for Chimeric RNAs from Gene Fusions and Exon-Skipping Events in Non–Small Cell Lung Cancer. The Journal of Molecular Diagnostics 21:2, pages 352-365.
Crossref
Arthur Aubry, Stéphane Galiacy & Michèle Allouche. (2019) Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides. Cancers 11:3, pages 275.
Crossref
Emily Duffield. 2019. Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners 51 64 .
Xuan Liu, Tao Shen, Blaine H M Mooers, Frank Hilberg & Jie Wu. (2018) Drug resistance profiles of mutations in the RET kinase domain. British Journal of Pharmacology 175:17, pages 3504-3515.
Crossref
Silky Bedi, Shah A. Khan, Majed M. AbuKhader, Perwez Alam, Nasir A. Siddiqui & Asif Husain. (2018) A comprehensive review on Brigatinib – A wonder drug for targeted cancer therapy in non-small cell lung cancer. Saudi Pharmaceutical Journal 26:6, pages 755-763.
Crossref
Zachary Schrank, Gagan Chhabra, Leo Lin, Tsatsral Iderzorig, Chike Osude, Nabiha Khan, Adijan Kuckovic, Sanjana Singh, Rachel Miller & Neelu Puri. (2018) Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance. Cancers 10:7, pages 224.
Crossref
Rubens Barros Costa, Ricardo L.B. Costa, Sarah M. Talamantes, Jason B. Kaplan, Manali A. Bhave, Alfred Rademaker, Corinne Miller, Benedito A. Carneiro, Devalingam Mahalingam & Young Kwang Chae. (2018) Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer . Oncotarget 9:31, pages 22137-22146.
Crossref
Muhammad Latif, Zaman Ashraf, Sulman Basit, Abdul Ghaffar, Muhammad Sohail Zafar, Aamer Saeed & Sultan Ayoub Meo. (2018) Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments. RSC Advances 8:30, pages 16470-16493.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.